Clinical Trial Update: Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated stopping versus continuing long-term mepolizumab in adults with severe eosinophilic asthma; results were posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Mepolizumab (mepolizumab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Asthma | Phase 3 | Status: COMPLETED | Results posted: 2020-02-05